Sandoz Group (OTCMKTS:SDZNY) Downgraded by UBS Group to “Hold”

Sandoz Group (OTCMKTS:SDZNY) was downgraded by equities research analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Separately, BNP Paribas lowered Sandoz Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 2nd.

Sandoz Group Trading Up 4.1 %

OTCMKTS SDZNY opened at $48.61 on Monday. Sandoz Group has a fifty-two week low of $27.79 and a fifty-two week high of $48.66. The stock has a 50-day simple moving average of $43.52 and a two-hundred day simple moving average of $43.20.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.